bioAffinity Technologies Scores $3.3M Investment Boost to Revolutionize Early-Stage Lung Cancer Diagnosis

bioAffinity Technologies, Inc. is excited to announce a successful funding round in which the company raised $3,300,000. This significant investment underscores the strong market and clinical need for advanced, noninvasive diagnostic solutions for early-stage lung cancer and other lung-related diseases. With its pioneering product, CyPath® Lung, bioAffinity Technologies is at the forefront of transforming lung cancer diagnostics. CyPath® Lung is a novel test designed to deliver high sensitivity, specificity, and accuracy in detecting early-stage lung cancer, providing a much-needed alternative for patients who present with pulmonary nodules on their scans. The test’s noninvasive nature offers substantial clinical advantages, including the potential to reduce unnecessary invasive procedures, decrease patient anxiety, and ultimately lower overall healthcare costs. This latest funding will be primarily directed toward further development and optimization of the CyPath® Lung test, as well as supporting additional research to enhance its diagnostic performance. Furthermore, the funds will contribute to expanding clinical validation studies and scaling up manufacturing capabilities to meet growing demand. In partnership with Precision Pathology Services, which has licensed the technology for commercialization as a Laboratory Developed Test, bioAffinity Technologies is poised to broaden its market reach and accelerate its mission of improving patient outcomes. This infusion of capital marks a crucial step forward, empowering the team to deepen its commitment to innovation in noninvasive disease detection and reaffirming their dedication to enhancing survival rates and quality of life for countless patients facing the challenges of lung cancer.